Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559474 | 0.85 | TLR7 (0.48) | ACSS2KDM4EDRD2TBXA2RHTT | |
| SCHEMBL20280108 | 0.85 | TLR7 (0.48) | ACSS2KDM4EDRD2TBXA2RHTT | |
| Hydrochloric Acid SCHEMBL20266404 | 0.84 | TLR7 (0.47) | ACSS2KDM4EDRD2TBXA2RHTT | |
| SCHEMBL30474209 | 0.84 | TLR7 (0.48) | ACSS2KDM4EDRD2TBXA2RCNR2 | |
| SCHEMBL31413142 | 0.84 | ACSS2 (0.49) | ACSS2KDM4EDRD2TBXA2RALOX15 | |
| SCHEMBL25767043 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EDRD2TBXA2RCNR2 | |
| SCHEMBL26237230 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EDRD2TBXA2RALOX15 | |
| SCHEMBL31202954 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EDRD2TBXA2RALOX15 | |
| SCHEMBL30676114 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EDRD2TBXA2RALOX15 | |
| SCHEMBL20266433 | 0.83 | ACSS2 (0.46) | ACSS2KDM4EDRD2TBXA2RALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ACSS2 1914/4885KDM4E 4574/4885DRD2 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.